Showing results (311-320 of 326) with videos related to
Sort By:
Pageof 33
Clinical Transplantation|March 16, 2011
Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemiaR Brian Stevens, James T Lane, Brian P Boerner, et al.Frontiers in Immunology|December 20, 2021
Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in MiceRandall C Gunther, Vanthana Bharathi, Stephen D Miles, et al.Proceedings of the National Academy of Sciences of the United States of America|December 2, 2010
Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancerJean J Latimer, Jennifer M Johnson, Crystal M Kelly, et al.Plant Disease|January 31, 2022
Identification of Putative SDHI Target Site Mutations in the SDHB, SDHC, and SDHD Subunits of the Grape Powdery Mildew Pathogen Erysiphe necatorIoannis Stergiopoulos, Nathalie Aoun, Que van Huynh, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 29, 2018
Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 CasesJae-Hyung Chang, S Ali Husain, Dominick Santoriello, et al.Transplantation|August 2, 2014
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomesR Brian Stevens, Kirk W Foster, Clifford D Miles, et al.Science (New York, N.Y.)|September 29, 2018
Biosynthesis of the neurotoxin domoic acid in a bloom-forming diatomJohn K Brunson, Shaun M K McKinnie, Jonathan R Chekan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2021
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerD Miles, J Gligorov, F André, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationD Miles, E Ciruelos, A Schneeweiss, et al.Pageof 33